Business Wire

NFT Marketplace IOGINALITY Launches, Offering Comprehensive Infrastructure for Digital Art and Bringing Emerging Galleries into the Web3 Fold

22.5.2023 17:33:00 EEST | Business Wire | Press release

Share

IOGINALITY, the first art NFT platform aimed at emerging galleries, today announced its launch to allow galleries and collectors a seamless and fully compliant platform to transact and benefit from the potential of tokenised art.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005427/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IOGINALITY’s interface (Graphic: Business Wire)

Providing emerging galleries with equitable access to resources

With a target of becoming the go-to platform for art market stakeholders worldwide, IOGINALITY’s initial focus is on bringing legal and technical support and resources to young galleries transitioning to the Web3 world, by offering an ecosystem solution and proven legal structure to accelerate new market entrants globally.

IOGINALITY exclusively permits galleries to mint NFTs, guaranteeing that customers deal only with compliant sellers and verified art. In the same vein, IOGINALITY also provides access to trusted buyers by using automated Know-Your-Customer and Know-Your-Business checks, to allow galleries to connect with collectors confidently and provide a trustworthy solution for the financial and legal security of customers’ deals, in line with the ever-evolving regulatory landscape across jurisdictions.

Simplified fee structure for all stakeholders

Powered by smart contracts, IOGINALITY facilitates instantaneous and straightforward transactions for galleries, artists, and art dealers. At the moment of minting, the NFTs’ selling prices and royalties are immediately aligned across all stakeholders, circumventing the costs, obscurities, and delays that often impede innovation. More importantly, the IOGINALITY platform offers the possibility of appointing an unlimited number of receivers involved in the transaction.

Formed under a partnership with Midas Investments, a major international crypto fund based in Hong Kong, IOGINALITY is co-founded by internationally-renowned lawyers Ekaterina Smirnova, and Yuriy Brisov. Together, they bring extensive experience in digital markets, delivering legal, economic and strategic consulting services, as well as a critical awareness of crypto, NFT and securities regulations.

Commenting on the launch, Ekaterina Smirnova, Founder and CEO, said: “IOGINALITY was established as a direct remedy to the common issues facing the NFT market surrounding a lack of transparency, susceptibility to fraud and laundering as well as equitable access to forward-looking legal support resources. As hype around NFTs fades and the professionals remain, the industry is ripe for fundamental transformation. Emerging galleries are repeatedly expressing a keen desire to embrace Web3 and it is important that the industry creates the necessary hand railings to enable their adoption, while setting the standard for accessibility, professionalism, security and trust. IOGINALITY addresses this by levelling the playing field to allow more galleries to join the digital revolution, ushering in a new world order characterised by greater representation.”

Participation from global emerging galleries

At launch, IOGINALITY will first feature collections from Alisa Gallery, a contemporary art gallery in Dubai, imnotART, Chicago’s first NFT art gallery, as well as Web3 creative studio, Wizara. These partnerships allow IOGINALITY to accelerate the market entry of galleries globally, as part of its core mission to enrich an asymmetrical and closed world with quality digital art from all corners of the world. This global presence will be further facilitated by IOGINALITY’s growing network of NFT art ambassadors, who will drive new partnerships between art institutions, brands, and advertisers.

Adham Hafez, Co-founder, Creative Director, and Curator of Wizara added: “As a theorist and a curator, I have been interested in the fact that many legal scholars have moved to study Web3 and engage with how its potentials will radically not only change our understanding of art, but of society and how it manifests itself legally, artistically, politically, and culturally in general. Wizara sees in IOGINALITY a perfect partner in how it straddles an interest in practice as well as in theory, the way it equally invests in not only supporting artists to break through the market, but equally to assist them in understanding the contractual and legal matters of a world governed by Smart-contracts and blockchain-based agreements that will redefine art economy, and many of the gallerist-artists relations in our art worlds today.”

In line with its public launch, IOGINALITY has also launched an open source page ‘NFT Nightmares: Lessons Learned’. Hosted on the IOGINALITY website, the page features key takeaways from high-profile cases of Web3 fraud and malpractice including the stealing of Banksy’s Morons in 2021, and the infamous Hermes vs Rothschld lawsuit, which have deterred many collectors and galleries from exploring this realm. Open for all to participate in and submit personal experiences to feature in the case library, IOGINALITY’s comprehensive platform serves to contribute to the development and betterment of the Web3 community by increasing transparency and awareness of potential pitfalls.

In the long-term, IOGINALITY intends to expand its project and leverage its cross-industry expertise across art, culture, finance, technology, law and project management to implement NFT solutions across markets covering assets such as gems, collectible wines and real estate.

ENDS

About IOGINALITY

IOGINALITY is a digital art marketplace that combines the convenience of the Web3 world with the safety of art dealerships from top galleries and curators to allow artists, institutions, and collectors to transact and benefit from the potential of tokenised art on an accessible, seamless, and fully compliant platform. Through its focus on professionalism and artistic value, IOGINALITY’s platform serves to provide an ecosystem solution to industry concerns around legal, financial and technological facets.

Designed to facilitate greater representation of emerging galleries, IOGINALITY is reimagining the NFT art sector to become the go-to platform for art institutions and stakeholders worldwide to launch digital exhibitions and create NFT collections.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries
Wachsman
Zuhaili Marican
E: ioginality@wachsman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye